Literature DB >> 28721337

2016 Revision to the WHO Classification of Acute Myeloid Leukemia.

Ming Hong1, Guangsheng He1.   

Abstract

Entities:  

Year:  2017        PMID： 28721337      PMCID： PMC5506404          DOI： 10.1515/jtim-2016-0041

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN： 2224-4018


× No keyword cloud information.
  5 in total

1.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

Authors:  Susanne Schnittger; Frank Dicker; Wolfgang Kern; Nicole Wendland; Jana Sundermann; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

2.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Authors:  Jason H Mendler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Heiko Becker; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Jessica Kohlschmidt; Deedra Nicolet; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

3.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

4.  Does BCR/ABL1 positive acute myeloid leukaemia exist?

Authors:  Ellie P Nacheva; Colin D Grace; Diana Brazma; Katya Gancheva; Julie Howard-Reeves; Lena Rai; Rosemary E Gale; David C Linch; Robert K Hills; Nigel Russell; Alan K Burnett; Panagiotis D Kottaridis
Journal:  Br J Haematol       Date:  2013-03-25       Impact factor: 6.998

5.  A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Elzo de Wit; Britta A M Bouwman; Claudia Erpelinck; Vincent H J van der Velden; Marije Havermans; Roberto Avellino; Kirsten van Lom; Elwin J Rombouts; Mark van Duin; Konstanze Döhner; H Berna Beverloo; James E Bradner; Hartmut Döhner; Bob Löwenberg; Peter J M Valk; Eric M J Bindels; Wouter de Laat; Ruud Delwel
Journal:  Cell       Date:  2014-04-03       Impact factor: 41.582
  5 in total
  2 in total

1.  MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Authors:  Maro Ohanian; Uri Rozovski; Rashmi Kanagal-Shamanna; Lynne V Abruzzo; Sanam Loghavi; Tapan Kadia; Andrew Futreal; Kapil Bhalla; Zhuang Zuo; Yang O Huh; Sean M Post; Peter Ruvolo; Guillermo Garcia-Manero; Michael Andreeff; Steven Kornblau; Gautam Borthakur; Peter Hu; L Jeffrey Medeiros; Koichi Takahashi; Marisa J Hornbaker; Jianhua Zhang; Graciela M Nogueras-González; Xuelin Huang; Srdan Verstovsek; Zeev Estrov; Sherry Pierce; Farhad Ravandi; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jorge E Cortes
Journal:  Leuk Lymphoma       Date:  2018-05-09

2.  Identification of a novel long non-coding RNA within RUNX1 intron 5.

Authors:  Nicolás Schnake; Marcela Hinojosa; Soraya Gutiérrez
Journal:  Hum Genomics       Date:  2019-07-31       Impact factor: 4.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.